The study identifies that the NAB- and EB-resistance determinants in MRSA are distinct, differing in their resistance profiles to nucleic acid-binding compounds.
Distinct MRSA resistance determinants suggest independent mechanisms; hypothesis-generating and requires validation before clinical consideration.
The majority of methicillin-resistant Staphylococcus aureus isolated in Australia since 1980 carries a determinant encoding resistance to a variety of nucleic acid-binding (NAB) compounds, including ethidium bromide (EB) acriflavine and propamidine isothionate. In addition, an EB-resistance determinant is frequently located on conjugative plasmids encoding aminoglycoside resistance. A comparison of these two determinants revealed that the EB-resistance determinant also encoded resistance to several NAB compounds. However, the NAB- and the EB-resistance determinants differed in both the number of NAB-compounds to which they expressed resistance, and the level of resistance expressed towards these compounds. Whilst these 2 determinants have several features in common, the results suggest that the NAB- and EB-resistance determinants are not identical.
No takes yet. Share an insight, caveat, or question.
Emslie et al. (1985) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: